登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301234 证券简称：五洲医疗 公告编号：2025-036 安徽宏宇五洲医疗器械股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或者重大 遗漏。 三、备查文件 1、辞职报告； 2、2025年第一次职工代表大会决议。 特此公告。 安徽宏宇五洲医疗器械股份有限公司 一、非独立董事辞职情况 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）董事会于近日收到公司非独立董事潘岚岚女士 的书面辞职报告，因公司治理结构及内部工作调整，潘岚岚女士申请辞去第三届董事会非独立董事职 务，辞去上述职务后潘岚岚女士仍在公司担任董事会秘书、副总经理职务。 根据《中华人民共和国公司法》及《公司章程》等有关规定，潘岚岚女士辞职不会导致公司董事会人数 低于法定最低人数，不会影响公司董事会的正常运行，亦不会对公司的日常经营管理及未来发展产生不 利影响，潘岚岚女士的辞职报告自送达董事会之日起生效。潘岚岚女士原任期届满之日为2026年11月16 日，截至本公告披露日，潘岚岚女士直接持有公司股份 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-036 安徽宏宇五洲医疗器械股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）董事会于近日收 到公司非独立董事潘岚岚女士的书面辞职报告，因公司治理结构及内部工作调整， 潘岚岚女士申请辞去第三届董事会非独立董事职务，辞去上述职务后潘岚岚女士 仍在公司担任董事会秘书、副总经理职务。 根据《中华人民共和国公司法》及《公司章程》等有关规定，潘岚岚女士辞 职不会导致公司董事会人数低于法定最低人数，不会影响公司董事会的正常运行， 亦不会对公司的日常经营管理及未来发展产生不利影响，潘岚岚女士的辞职报告 自送达董事会之日起生效。潘岚岚女士原任期届满之日为 2026 年 11 月 16 日， 截至本公告披露日，潘岚岚女士直接持有公司股份 220,450 股，经核查，潘岚岚 女士不存在应当履行而未履行的承诺事项，其辞职后将继续严格遵守《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市公司 董事和高级管理人员所持本公司股份及其变动管理规则》《深圳证券交易所上市 公司自律监管指引 ...

证券之星消息，截至2025年12月8日收盘，五洲医疗(301234)报收于39.76元，上涨2.47%，换手率 2.66%，成交量1.81万手，成交额7189.95万元。 12月8日的资金流向数据方面，主力资金净流入329.85万元，占总成交额4.59%，游资资金净流入514.0 万元，占总成交额7.15%，散户资金净流出843.85万元，占总成交额11.74%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-08 | 39.76 | 2.47% | 329.85万 | 4.59% | 514.00万 | 7.15% | -843.85万 | -11.74% | | 2025-12-05 | 38.80 | 5.15% | ● 111.15万 | 2.16% | 218.75万 | 4.26% | -329.91万 | -6.42% | | 2025-12-04 | | 36. ...

登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司名称：安徽宏宇五洲医疗器械股份有限公司 股票上市地点：深圳证券交易所 股票简称：五洲医疗 股票代码：301234 信息披露义务人：太湖宏辉医疗管理合伙企业（有限合伙） 住所：安徽省安庆市太湖县经济开发区观音路318号 通信地址：安徽省安庆市太湖县经济开发区观音路2号 股份变动性质：股份数量减少，持股比例下降 签署日期：2025年11月 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号一一权益变动报告书》及相关的法律、法规和规范性文件编 写。 二、信息披露义务人签署本权益变动报告书已获得必要的授权和批准，其履行亦不违反信息披露义务人 章程或内部规则中的任何条款，或与之相冲突。 三、依据上述法律、法规的规定，本权益变动报告书已全面披露了信息披露义务人及其一致行动人在安 徽宏宇五洲医疗器械股份有限公司（以下简称"五洲医疗"或"上市公司"）拥有权益的股份变动情况。截 至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务人及其一致行动人没有通过任何其 ...

安徽宏宇五洲医疗器械股份有限公司 简式权益变动报告书 信息披露义务人：太湖宏辉医疗管理合伙企业（有限合伙） 住所：安徽省安庆市太湖县经济开发区观音路 318 号 通信地址：安徽省安庆市太湖县经济开发区观音路 2 号 股份变动性质：股份数量减少，持股比例下降 签署日期：2025 年 11 月 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收购管 理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》 及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本权益变动报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 上市公司名称：安徽宏宇五洲医疗器械股份有限公司 股票上市地点：深圳证券交易所 股票简称：五洲医疗 股票代码：301234 三、依据上述法律、法规的规定，本权益变动报告书已全面披露了信息披露义务人 及其一致行动人在安徽宏宇五洲医疗器械股份有限公司（以下简称"五洲医疗"或"上 市公司"）拥有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的持股 信息外，信息披露义务人及其一 ...

Core Viewpoint - Wuzhou Medical (301234) experienced a decline in stock price, closing at 39.3 yuan on November 18, 2025, with a drop of 2.19% and a trading volume of 9,135 hands, amounting to a total transaction value of 36.3 million yuan [1] Group 1: Stock Performance and Trading Data - On November 18, 2025, the net outflow of main funds was 626.71 thousand yuan, accounting for 17.26% of the total transaction value, while retail investors saw a net inflow of 405.29 thousand yuan, representing 11.16% of the total [1] - The stock's performance over the past five days shows a downward trend, with the highest closing price at 41.29 yuan on November 13, 2025, and a total net outflow of main funds on November 17 and 18 [2] Group 2: Financial Metrics and Industry Comparison - Wuzhou Medical's total market value is 2.672 billion yuan, significantly lower than the industry average of 11.405 billion yuan, ranking 112 out of 124 in the medical device industry [3] - The company's net profit for the first three quarters of 2025 was 18.51 million yuan, a decrease of 46.09% year-on-year, with a gross margin of 14.22%, which is substantially below the industry average of 51.22% [3] - The company's return on equity (ROE) stands at 2.43%, outperforming the industry average of 0.15%, indicating some efficiency in generating profits from equity [3]

Core Points - The article reports on the recent shareholding changes of Wuzhou Medical (301234), highlighting that on November 14, 2025, the company’s secretary and executives, including Pan Lanlan, reduced their holdings by a total of 13,000 shares, representing 0.0019% of the total share capital [1] - The stock price of Wuzhou Medical decreased by 0.94% on the same day, closing at 40.9 yuan [1] Summary of Shareholding Changes - On November 14, 2025, Pan Lanlan, the company secretary, sold 1,300 shares at an average price of 41.56 yuan, reducing her holdings to 244,000 shares [1] - On November 13, 2025, Zhou Lexiang sold 40,000 shares at an average price of 41.05 yuan, bringing his total holdings down to 422,500 shares [1] - On November 12, 2025, Pan Lanlan sold 7,200 shares at an average price of 39.95 yuan, while Zhou Lexiang sold 5,000 shares at 40.50 yuan [1] - The article provides a detailed table of shareholding changes for the past six months, indicating multiple transactions by executives [1] Current Shareholding Status - The current shareholding status of Wuzhou Medical executives shows that Huang Fan holds 16.43 million shares, Zhang Hongyu holds 6.12 million shares, and Xiang Bingyi holds 13.77 million shares [2] - Pan Lanlan's current holding after the recent transactions is 244,000 shares [2] - The financing data indicates a net inflow of 6.08 million in the last five days, with an increase in financing balance, while there was no net inflow in securities lending [2]

Core Viewpoint - The stock of Wuzhou Medical (301234) has shown a decline in price and mixed capital flow, indicating potential challenges in market performance and investor sentiment [1][2]. Financial Performance - As of November 17, 2025, Wuzhou Medical's stock closed at 40.18 yuan, down 1.76% with a trading volume of 11,200 hands and a transaction amount of 44.91 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 128 million yuan, a year-on-year decrease of 1.51%, and a net profit attributable to shareholders of 7.99 million yuan, down 36.39% year-on-year [3]. - For the first three quarters of 2025, the company's main revenue was 345 million yuan, up 0.82% year-on-year, while the net profit decreased by 46.09% to 18.51 million yuan [3]. Capital Flow Analysis - On November 17, 2025, the net inflow of main funds was 695,700 yuan, accounting for 1.55% of the total transaction amount, while retail investors experienced a net outflow of 2.34 million yuan, representing 5.20% of the total [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant retail outflows on November 14 and 13, indicating a potential shift in investor confidence [2]. Industry Comparison - Wuzhou Medical's total market value is 2.732 billion yuan, significantly lower than the industry average of 11.459 billion yuan, ranking 111 out of 124 in the medical device sector [3]. - The company's net profit margin stands at 5.36%, below the industry average of 9.57%, and its gross margin is 14.22%, compared to the industry average of 51.22%, indicating operational challenges [3].

Core Viewpoint - The report outlines the equity change of Anhui Hongyu Wuzhou Medical Equipment Co., Ltd. (Wuzhou Medical), indicating a reduction in shareholding by the information disclosing party, Taihu Honghui Medical Management Partnership (Limited Partnership) [1][2]. Group 1: Information Disclosure Obligations - The report is prepared in accordance with the Securities Law of the People's Republic of China and relevant regulations [1]. - The information disclosing party confirms that the report does not contain false records, misleading statements, or significant omissions, and assumes legal responsibility for its accuracy and completeness [2][10]. Group 2: Equity Change Details - The equity change is based on the information disclosing party's financial planning, involving a reduction of shares through centralized bidding [4][6]. - As of the report's signing date, the information disclosing party and its concerted actors have not increased or decreased their shareholdings in the company through other means [2][4]. Group 3: Shareholding Structure - The information disclosing party's concerted actor, Zou Aiying, holds 4,080,000 shares, all of which are pledged [7]. - The total share capital of the company is 68,000,000 shares, and the report provides specific details on the shareholding before and after the equity change [6][8]. Group 4: Impact on the Company - The equity change will not lead to a change in control of the company, nor will it affect the main business operations, financial independence, or governance structure [8].

Group 1 - The company held its first extraordinary general meeting of shareholders in 2025 on November 13, 2025, with a combination of on-site and online voting [3][4][6] - A total of 31 shareholders attended the meeting, representing 48,814,500 shares, which accounts for 71.7860% of the total voting shares [6] - The meeting was convened by the company's third board of directors and was deemed legal and compliant with relevant laws and regulations [5][46] Group 2 - All proposals presented at the meeting were approved without any dissenting votes [2][9] - The proposal to amend the company's articles of association received 48,806,100 votes in favor, representing 99.9828% of the valid votes cast [9][12] - The proposal to amend the governance rules and other related proposals also received similar overwhelming support, with no votes against [12][15][18] Group 3 - The legal opinions provided by Anhui Tianhe Law Firm confirmed that the meeting's convening, attendance, voting procedures, and results were in accordance with the Company Law and other relevant regulations [46] - The company has made available documents related to the meeting, including the resolutions and legal opinions for public reference [47]